Leukemia:科学家发现WT1-MEG3信号通路有望成为治疗AML的新靶点

2017-12-22 MedSci MedSci原创

WT1-MEG3轴能抑制肿瘤生长,有望成为有效的治疗AML的一系列潜在的靶点。

急性髓系白血病是一种常见的成人恶性髓系细胞疾病,其产生的造血前体细胞克隆极具异质性,这些造血前体细胞表现出不同的生物学表型以及疾病进展特征,这也造成了标准化治疗效果的不确定性。为了改善AML的治疗方法,提高疾病的治愈率,目前基础与临床研究集中寻找AML的基因特征,以希望更深一步的理解AML的发病机制,从而寻找新的治疗靶点以期提高疾病的治愈率。

长非编码RNAs(Long non-coding RNAs, IncRNAs)在肿瘤发生过程中发挥着重要的作用,以最近的发现的髓系相关的IncRNA MEG3为例,它能够通过提高肿瘤抑制因子p53蛋白水平并且能够促进p53结合与它的下游靶基因,从而抑制肿瘤的生长。然而TP53突变能够导致野生型具有肿瘤抑制功能的p53丢失,而这种突变存在于多种肿瘤细胞内,包括AML。也有研究表明MEG3与RB信号通路调控有关而具有调节细胞增殖的能力,这就表明MEG3有可能参与非p53依赖的抑癌信号通路。

转录因子WT1能够在转录水平激活MEG3,WT1在AML发生中通常会因表观遗传修饰沉默或基因突变而功能失调。MEG3被认为是WT1分子的新的下游靶位点。TET2能通过将5-甲基胞嘧啶转换为5-羟甲基胞嘧啶而是DNA序列去甲基化。AML细胞中通常能够发现TET2基因突变,并且TET2突变也能够促进AML的疾病进展。研究发现WT1与TET2能互相结合,并且WT1可以募集TET2到WT1的靶基因上,这就表明TET2能够参与AML疾病中WT1的转录活性。

这个研究发现,MGE3失活能够通过p53依赖和非依赖途径促进AML白血病发生。进一步的分析表明WT1能够特异性的结合于MEG3的启动子激活转录,而TET2和WT1在AML发病过程中具有相关性。总之,TET2可以作为WT1的共同作用因子促进MEG3的转录。由于WT1-MEG3轴能抑制肿瘤生长,这个研究为有效的治疗AML提供了一系列潜在的靶点。

原文出处:Lyu Y,Lou J, Yang Y et al.Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.Leukemia. 2017 Dec;31(12):2543-2551. doi: 10.1038/leu.2017.116. Epub 2017 Apr 12.

本文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2159369, encodeId=408a215936915, content=科学家发现WT1-<a href='/topic/show?id=9fb41066e1c5' target=_blank style='color:#2F92EE;'>#MEG3#</a>信号通路有望成为治疗<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>的新靶点,<a href='/topic/show?id=eb2152482d7' target=_blank style='color:#2F92EE;'>#急性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106671, encryptionId=9fb41066e1c5, topicName=MEG3), TopicDto(id=2435, encryptionId=11fe2435ff, topicName=AML), TopicDto(id=52482, encryptionId=eb2152482d7, topicName=急性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Sep 24 01:09:08 CST 2023, time=2023-09-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1703479, encodeId=32b51e034795e, content=<a href='/topic/show?id=42f818e72fe' target=_blank style='color:#2F92EE;'>#WT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18772, encryptionId=42f818e72fe, topicName=WT1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639f30510424, createdName=闆锋旦, createdTime=Sun Jul 01 21:49:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802504, encodeId=1ddc180250463, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 05 23:49:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275238, encodeId=13c62e52388b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 04 06:38:10 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288238, encodeId=181b1288238b6, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539643, encodeId=16a615396431d, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2023-09-24 侠胆医心 来自上海

    科学家发现WT1-#MEG3#信号通路有望成为治疗#AML#的新靶点,#急性髓系白血病#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2159369, encodeId=408a215936915, content=科学家发现WT1-<a href='/topic/show?id=9fb41066e1c5' target=_blank style='color:#2F92EE;'>#MEG3#</a>信号通路有望成为治疗<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>的新靶点,<a href='/topic/show?id=eb2152482d7' target=_blank style='color:#2F92EE;'>#急性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106671, encryptionId=9fb41066e1c5, topicName=MEG3), TopicDto(id=2435, encryptionId=11fe2435ff, topicName=AML), TopicDto(id=52482, encryptionId=eb2152482d7, topicName=急性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Sep 24 01:09:08 CST 2023, time=2023-09-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1703479, encodeId=32b51e034795e, content=<a href='/topic/show?id=42f818e72fe' target=_blank style='color:#2F92EE;'>#WT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18772, encryptionId=42f818e72fe, topicName=WT1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639f30510424, createdName=闆锋旦, createdTime=Sun Jul 01 21:49:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802504, encodeId=1ddc180250463, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 05 23:49:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275238, encodeId=13c62e52388b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 04 06:38:10 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288238, encodeId=181b1288238b6, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539643, encodeId=16a615396431d, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2018-07-01 闆锋旦
  3. [GetPortalCommentsPageByObjectIdResponse(id=2159369, encodeId=408a215936915, content=科学家发现WT1-<a href='/topic/show?id=9fb41066e1c5' target=_blank style='color:#2F92EE;'>#MEG3#</a>信号通路有望成为治疗<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>的新靶点,<a href='/topic/show?id=eb2152482d7' target=_blank style='color:#2F92EE;'>#急性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106671, encryptionId=9fb41066e1c5, topicName=MEG3), TopicDto(id=2435, encryptionId=11fe2435ff, topicName=AML), TopicDto(id=52482, encryptionId=eb2152482d7, topicName=急性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Sep 24 01:09:08 CST 2023, time=2023-09-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1703479, encodeId=32b51e034795e, content=<a href='/topic/show?id=42f818e72fe' target=_blank style='color:#2F92EE;'>#WT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18772, encryptionId=42f818e72fe, topicName=WT1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639f30510424, createdName=闆锋旦, createdTime=Sun Jul 01 21:49:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802504, encodeId=1ddc180250463, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 05 23:49:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275238, encodeId=13c62e52388b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 04 06:38:10 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288238, encodeId=181b1288238b6, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539643, encodeId=16a615396431d, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2159369, encodeId=408a215936915, content=科学家发现WT1-<a href='/topic/show?id=9fb41066e1c5' target=_blank style='color:#2F92EE;'>#MEG3#</a>信号通路有望成为治疗<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>的新靶点,<a href='/topic/show?id=eb2152482d7' target=_blank style='color:#2F92EE;'>#急性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106671, encryptionId=9fb41066e1c5, topicName=MEG3), TopicDto(id=2435, encryptionId=11fe2435ff, topicName=AML), TopicDto(id=52482, encryptionId=eb2152482d7, topicName=急性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Sep 24 01:09:08 CST 2023, time=2023-09-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1703479, encodeId=32b51e034795e, content=<a href='/topic/show?id=42f818e72fe' target=_blank style='color:#2F92EE;'>#WT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18772, encryptionId=42f818e72fe, topicName=WT1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639f30510424, createdName=闆锋旦, createdTime=Sun Jul 01 21:49:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802504, encodeId=1ddc180250463, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 05 23:49:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275238, encodeId=13c62e52388b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 04 06:38:10 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288238, encodeId=181b1288238b6, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539643, encodeId=16a615396431d, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2018-01-04 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2159369, encodeId=408a215936915, content=科学家发现WT1-<a href='/topic/show?id=9fb41066e1c5' target=_blank style='color:#2F92EE;'>#MEG3#</a>信号通路有望成为治疗<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>的新靶点,<a href='/topic/show?id=eb2152482d7' target=_blank style='color:#2F92EE;'>#急性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106671, encryptionId=9fb41066e1c5, topicName=MEG3), TopicDto(id=2435, encryptionId=11fe2435ff, topicName=AML), TopicDto(id=52482, encryptionId=eb2152482d7, topicName=急性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Sep 24 01:09:08 CST 2023, time=2023-09-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1703479, encodeId=32b51e034795e, content=<a href='/topic/show?id=42f818e72fe' target=_blank style='color:#2F92EE;'>#WT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18772, encryptionId=42f818e72fe, topicName=WT1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639f30510424, createdName=闆锋旦, createdTime=Sun Jul 01 21:49:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802504, encodeId=1ddc180250463, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 05 23:49:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275238, encodeId=13c62e52388b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 04 06:38:10 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288238, encodeId=181b1288238b6, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539643, encodeId=16a615396431d, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2017-12-24 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=2159369, encodeId=408a215936915, content=科学家发现WT1-<a href='/topic/show?id=9fb41066e1c5' target=_blank style='color:#2F92EE;'>#MEG3#</a>信号通路有望成为治疗<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>的新靶点,<a href='/topic/show?id=eb2152482d7' target=_blank style='color:#2F92EE;'>#急性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106671, encryptionId=9fb41066e1c5, topicName=MEG3), TopicDto(id=2435, encryptionId=11fe2435ff, topicName=AML), TopicDto(id=52482, encryptionId=eb2152482d7, topicName=急性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Sep 24 01:09:08 CST 2023, time=2023-09-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1703479, encodeId=32b51e034795e, content=<a href='/topic/show?id=42f818e72fe' target=_blank style='color:#2F92EE;'>#WT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18772, encryptionId=42f818e72fe, topicName=WT1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639f30510424, createdName=闆锋旦, createdTime=Sun Jul 01 21:49:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802504, encodeId=1ddc180250463, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 05 23:49:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275238, encodeId=13c62e52388b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 04 06:38:10 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288238, encodeId=181b1288238b6, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539643, encodeId=16a615396431d, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 24 01:49:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]

相关资讯

Blood:FF-10101,一种新型FLT3抑制剂,为携带FLT3突变的AML患者带来新的希望。

FLT3激活性突变,是与急性粒细胞白血病(AML)预后不良相关的最常见的遗传突变。尽管现临床上已经研发了多种FLT3抑制剂,但由于药物代谢差或低选择性、安全性差,尚无一种一代抑制剂在单药治疗中表现出临床疗效。近期,一种选择性FLT3抑制剂,quizartinib,在临床研究中证实效果良好。然而,在疾病的进展过程中出现了几种耐药性突变。为克服这些问题,Takeshi Yamaura等人研发了一种新型

Nat Cell Biol:增加脂肪细胞竟能抗癌!科学家或找到白血病全新疗法,可使造血功能增强 40%,并显著抑制癌细胞生长

近日,来自加拿大 McMaster 大学干细胞与癌症研究所 Mickie Bhatia 教授所领导的研究团队发现,红骨髓(具有造血功能的骨髓,后面简称骨髓,虽然人体内也有富含脂肪细胞的黄骨髓,但是这里面的脂肪细胞不乐意帮红骨髓)中的脂肪细胞是人类骨髓中健康血细胞发育成熟所必须的。急性髓性白血病引发的机体造血功能障碍,就是通过抑制骨髓脂肪细胞生成实现的。

J Clin Oncol:急性髓性白血病老年患者的终末期治疗有待改善!

急性髓系白血病(AML)老年人的发病率逐年上升,平均发病年龄为67岁,老年患者易合并脏器功能不全,预后较差。2017年10月,发表在《J Clin Oncol》的一项由美国科学家进行的基于人群、回顾性、队列研究,考察了AML老年患者的终末期医疗保健情况。

Leuk Lymphoma:急性白血病老年患者应采用何种治疗方案?

2018年2月,发表在《Leuk Lymphoma》的一项由美国科学家进行的研究,考察了老年AML患者使用常规诱导策略的结局,并试图确定针对老年人有效的治疗方案和最佳选择。

Nat Cell Biol:增加脂肪细胞竟能抗癌!

近日,来自加拿大 McMaster 大学干细胞与癌症研究所 Mickie Bhatia 教授所领导的研究团队发现,红骨髓(具有造血功能的骨髓,后面简称骨髓,虽然人体内也有富含脂肪细胞的黄骨髓,但是这里面的脂肪细胞不乐意帮红骨髓)中的脂肪细胞是人类骨髓中健康血细胞发育成熟所必须的。急性髓性白血病引发的机体造血功能障碍,就是通过抑制骨髓脂肪细胞生成实现的。

Nature:重磅级成果!科学家发现关键酶类的错误调节或会诱发白血病和脑癌

来自德国癌症研究中心等机构的研究人员通过研究发现,机体中负责分解食物中特殊氨基酸的关键酶类或许在脑癌和白血病发病上扮演着关键角色,相关研究刊登于国际杂志Nature上,文章中,研究人员阐明了能量代谢和所谓的表观遗传学代码的关联,癌症干细胞的DNA标签能够帮助决定基因的活性,以及多种细胞功能,同时研究者还认为阻断该酶类的活性或许能帮助有效抵御癌症的发生。